New Shingles Vaccine

What is shingles? 

Shingles, a painful and sometimes debilitating nerve inflammation and blistering skin rash, is caused by the same virus that causes chickenpox. Anyone who has had chickenpox is susceptible to it many years later. Signs and symptoms include a very painful/sensitive rash (usually wraps around the back to the front of body), fluid filled blisters that can break open and crust over, itching, sensitivity to touch, pain/numbness/burning, fatigue, headache, fever and sensitivity to light.

New vaccination now available
A new vaccine approved by the U.S. Food and Drug Administration (FDA) in 2017, Shingrix, is about 90-97 percent effective at preventing shingles. Shingrix, a two-dose vaccine taken two to six months apart, is not a live vaccine. It’s indicated for adults 50 years of age and older.

Zostavax®, the shingles vaccination in use since 2006, is a one-dose, live vaccination for adults 50 years of age and older and reduces the risk of developing shingles by about 51-70 percent. Until now, Zostavax has been the only vaccine choice for the prevention of shingles.

Standard ACA coverage for preventive services effective February 1, 2018
Effective February 1, 2018, Shingrix was added to the standard coverage recommendation for Affordable Care Act (ACA) preventive services for men and women, age 50 and older, regardless if they have already received Zostavax. This vaccine is also recommended for individuals that have already had shingles, as it could help prevent flare-ups of the virus. There will be no prior authorization, but a quantity limit of two injections will apply.  The vaccine will be covered under the preventive benefit at 100% in network per ACA guidelines.